LOQPF yields 59.70% · JNJ yields 2.13%● Live data
📍 LOQPF pulled ahead of the other in Year 1
Combined, LOQPF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LOQPF + JNJ for your $10,000?
accesso Technology Group plc, together with its subsidiaries, develops technology solutions for the attractions and leisure industry in the United Kingdom, other European countries, Australia, the South Pacific, the United States, Canada, and Central and South America. The company operates through Ticketing and Distribution, and Guest Experience segments. It offers ticketing solutions for fairs and festivals, performing arts, ski, theme parks, tours and attractions, water parks, and zoos and aquariums, as well as cultural facilities. The company also offers various solutions, such as accesso LoQueue, a virtual queuing solution; the experience engine, an experience management platform; and accesso Passport ticketing suite, which provides season pass, group tickets, meal vouchers, and other services. In addition, it provides accesso Siriusware, which offers software solutions comprising ticketing and admissions, memberships, reservations, resource scheduling, retail, food service, gift cards, kiosks, and ecommerce; and accesso ShoWare ticketing solutions for box office, kiosk, online, mobile, call center, and social media sales. The company was formerly known as Lo-Q plc and changed its name to accesso Technology Group plc in November 2013. accesso Technology Group plc was incorporated in 2000 and is based in Twyford, the United Kingdom.
Full LOQPF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.